L'uso dei farmaci oftalmologici nella popolazione pediatrica in Italia

Translated title of the contribution: Topical ocular drugs in the Italian paediatric population

Filomena Fortinguerra, Antonio Clavenna, Maurizio Bonati

Research output: Contribution to journalArticle

Abstract

Aim - A study was planned to analyse the availability and the licensing status of ocular drugs marketed in Italy and evaluate the evidence on their safety and efficacy in paediatric population. Materials and methods - A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged <18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation. Results - In all, of 195 ocular drugs identified, 130 (67%) of which were marketed in Italy, 62 (48%) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21% of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46%) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56% completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies. Conclusions - There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.

Original languageItalian
Pages (from-to)311-318
Number of pages8
JournalMedico e Bambino
Volume30
Issue number5
Publication statusPublished - May 2011

Fingerprint

Pediatrics
Pharmaceutical Preparations
Population
Italy
Licensure
Randomized Controlled Trials
Mydriatics
Registries
Clinical Trials
MEDLINE
Cyclosporine
Pharmacology
Safety
Therapeutics
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

L'uso dei farmaci oftalmologici nella popolazione pediatrica in Italia. / Fortinguerra, Filomena; Clavenna, Antonio; Bonati, Maurizio.

In: Medico e Bambino, Vol. 30, No. 5, 05.2011, p. 311-318.

Research output: Contribution to journalArticle

@article{b3c53d948957409ab1a2534650e1ee32,
title = "L'uso dei farmaci oftalmologici nella popolazione pediatrica in Italia",
abstract = "Aim - A study was planned to analyse the availability and the licensing status of ocular drugs marketed in Italy and evaluate the evidence on their safety and efficacy in paediatric population. Materials and methods - A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged <18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation. Results - In all, of 195 ocular drugs identified, 130 (67{\%}) of which were marketed in Italy, 62 (48{\%}) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21{\%} of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46{\%}) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56{\%} completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies. Conclusions - There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.",
keywords = "Drug therapy, Eye diseases, Paediatrics, Topical ocular drugs",
author = "Filomena Fortinguerra and Antonio Clavenna and Maurizio Bonati",
year = "2011",
month = "5",
language = "Italian",
volume = "30",
pages = "311--318",
journal = "Medico e Bambino",
issn = "1591-3090",
publisher = "Medico e Bambino",
number = "5",

}

TY - JOUR

T1 - L'uso dei farmaci oftalmologici nella popolazione pediatrica in Italia

AU - Fortinguerra, Filomena

AU - Clavenna, Antonio

AU - Bonati, Maurizio

PY - 2011/5

Y1 - 2011/5

N2 - Aim - A study was planned to analyse the availability and the licensing status of ocular drugs marketed in Italy and evaluate the evidence on their safety and efficacy in paediatric population. Materials and methods - A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged <18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation. Results - In all, of 195 ocular drugs identified, 130 (67%) of which were marketed in Italy, 62 (48%) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21% of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46%) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56% completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies. Conclusions - There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.

AB - Aim - A study was planned to analyse the availability and the licensing status of ocular drugs marketed in Italy and evaluate the evidence on their safety and efficacy in paediatric population. Materials and methods - A quantitative analysis was performed in order to evaluate the number of ocular drugs with a paediatric licence in Italy. A literature search was also performed in MEDLINE and EMBASE for randomized controlled trials (RCTs) concerning ophthalmic pharmacological therapy in children aged <18 years, published up to October 2010. A search in the international clinical trial registries and in the list of paediatric investigation plans (PIPs) approved by EMA was performed in order to find which ocular drugs are under paediatric investigation. Results - In all, of 195 ocular drugs identified, 130 (67%) of which were marketed in Italy, 62 (48%) with a paediatric licence. No published RCTs were found for one third of ocular drugs licensed for paediatric use in Italy, while 21% of all retrieved studies were related to 23 drugs not licensed for paediatric use. 59 (46%) of 128 retrieved RCTs regarded mydriatic/cycloplegic medications. 62 RCTs (56% completed) on 46 drugs, were found in the international clinical trial registries, while only 3 PIPs were approved by EMA. Cyclosporine and bevacizumab were the drugs involved in many ongoing studies. Conclusions - There is a need for further research and clinical development in the paediatric ophthalmic area, where the availability of effective and up-to-date treatments investigated in children remains a priority.

KW - Drug therapy

KW - Eye diseases

KW - Paediatrics

KW - Topical ocular drugs

UR - http://www.scopus.com/inward/record.url?scp=79957741553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957741553&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:79957741553

VL - 30

SP - 311

EP - 318

JO - Medico e Bambino

JF - Medico e Bambino

SN - 1591-3090

IS - 5

ER -